A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver
PHASE1CompletedINTERVENTIONAL
Enrollment
30
Participants
Timeline
Start Date
September 30, 1997
Study Completion Date
March 31, 2001
Conditions
Liver NeoplasmsNeoplasm Metastasis
Interventions
PROCEDURE
Isolated hepatic portal and arterial perfusion
DRUG
Melphalan
Trial Locations (1)
20892
National Cancer Institute (NCI), Bethesda
All Listed Sponsors
lead
National Cancer Institute (NCI)
NIH
NCT00001587 - A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver | Biotech Hunter | Biotech Hunter